Instil Bio Stock Today

TIL Stock  USD 7.16  0.09  1.27%   

Performance

Weakest

 
Weak
 
Strong

Odds Of Distress

Strong

 
High
 
Low
Instil Bio is selling for 7.16 as of the 28th of January 2026. This is a 1.27% up since the beginning of the trading day. The stock's lowest day price was 6.96. Instil Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 30th of October 2025 and ending today, the 28th of January 2026. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
19th of March 2021
Category
Healthcare
Classification
Health Care
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas. Instil Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.78 M outstanding shares of which 562 K shares are at this time shorted by investors with about 9.6 days to cover. More on Instil Bio

Moving together with Instil Stock

  0.83DRMA Dermata TherapeuticsPairCorr
  0.73VINC Vincerx Pharma CommonPairCorr
  0.76VYGR Voyager TherapeuticsPairCorr
  0.86SLN Silence Therapeutics PLC Downward RallyPairCorr

Moving against Instil Stock

  0.82MARUF Marubeni Earnings Call This WeekPairCorr
  0.75HLN Haleon plcPairCorr
  0.74CNOB ConnectOne Bancorp Earnings Call TomorrowPairCorr
  0.73VNDA Vanda PharmaceuticalsPairCorr
  0.69CAPR Capricor TherapeuticsPairCorr
  0.63KYTX Kyverna TherapeuticsPairCorr

Instil Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Old Names[Till Capital Ltd, TIPTEL, Trilogy International Limited]
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite Total, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Debt Levels
Instil Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Instil Bio's financial leverage. It provides some insight into what part of Instil Bio's total assets is financed by creditors.
Liquidity
Instil Bio has 86.89 M in debt with debt to equity (D/E) ratio of 0.12, which may show that the company is not taking advantage of profits from borrowing. Instil Bio has a current ratio of 8.34, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Instil to invest in growth at high rates of return.

Begin Period Cash Flow

9.15 Million
Instil Bio (TIL) is traded on NASDAQ Exchange in USA and employs 14 people. Instil Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 48.56 M. Instil Bio runs under Biotechnology sector within Health Care industry. The entity has 6.78 M outstanding shares of which 562 K shares are at this time shorted by investors with about 9.6 days to cover. Instil Bio has about 354.61 M in cash with (55.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.73.
Check Instil Bio Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Instil Bio is $48.56 Million. Over half of Instil Bio's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Instil Ownership Details

Instil Stock Institutional Holders

InstituionRecorded OnShares
Boxer Capital Management, Llc2025-06-30
70.7 K
Renaissance Technologies Corp2025-06-30
70.7 K
Northern Trust Corp2025-06-30
64.4 K
Assenagon Asset Management Sa2025-06-30
57.5 K
Blackrock Inc2025-06-30
50.7 K
Macquarie Group Ltd2025-06-30
50 K
Geode Capital Management, Llc2025-06-30
43.1 K
State Street Corp2025-06-30
17.6 K
Trexquant Investment Lp2025-06-30
17.4 K
Bml Capital Management Llc2025-06-30
534.9 K
Cpmg Inc2025-06-30
410.9 K
View Instil Bio Diagnostics

Instil Bio Historical Income Statement

At this time, Instil Bio's Interest Income is quite stable compared to the past year. Interest Expense is expected to rise to about 10.9 M this year, although the value of Net Interest Income is projected to rise to (2.2 M). View More Fundamentals

Instil Stock Against Markets

Instil Bio Corporate Management

Sandeep MDCFO OfficerProfile
Timothy MooreChief OfficerProfile
Bronson CrouchChairman CEOProfile
Sumita JDCompliance, LegalProfile
James MDChief OfficerProfile
Mark DudleyChief OfficerProfile
Robert MBBSHead DevelopmentProfile
When determining whether Instil Bio is a strong investment it is important to analyze Instil Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Instil Bio's future performance. For an informed investment choice regarding Instil Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Instil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Instil Stock please use our How to buy in Instil Stock guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Instil Bio. If investors know Instil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Instil Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.35)
Return On Assets
(0.15)
Return On Equity
(0.51)
The market value of Instil Bio is measured differently than its book value, which is the value of Instil that is recorded on the company's balance sheet. Investors also form their own opinion of Instil Bio's value that differs from its market value or its book value, called intrinsic value, which is Instil Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Instil Bio's market value can be influenced by many factors that don't directly affect Instil Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Instil Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Instil Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Instil Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.